NDC product
Atgam
NDC 0009-7224 · Pharmacia & Upjohn Company LLC
Key facts
| Product NDC | 0009-7224 |
|---|---|
| Proprietary name | Atgam |
| Nonproprietary name | EQUINE THYMOCYTE IMMUNE GLOBULIN |
| Substances | EQUINE THYMOCYTE IMMUNE GLOBULIN |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Pharmacia & Upjohn Company LLC |
| Product type | PLASMA DERIVATIVE |
| Marketing category | BLA |
| Application number | BLA103676 |
| Pharmacologic classes | Antibody-Surface Protein Interactions [MoA], Immunoglobulin G [EPC], Immunoglobulins [CS], Increased T Lymphocyte Destruction [PE], Lymphocyte Function Alteration [PE] |
| Marketing start | Nov 17, 1981 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: